Skip to main content

Illumina to Repurchase Up to $120M of Stock

NEW YORK (GenomeWeb News) – Illumina said today that its board of directors has approved the repurchase of up to $120 million of its common stock.
 
"Given the underlying strength of Illumina's business and the recent turbulence in the equity markets, we think our current stock price is undervalued,” said Illumina President and CEO Jay Flatley. “Therefore, we believe the stock buy-back program is in the best interests of our stockholders.”
 
Earlier this week, the firm posted third-quarter revenue growth of 54 percent to $150.3 million.
 
Illumina said that the purchases would be made on the open market or through privately negotiated transactions. It will fund the purchases with existing cash balances, it said.
 

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.